{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:49:28Z","timestamp":1789555768913,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001316","name":"University of Kent","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Reports"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.toxrep.2024.101732","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T17:56:59Z","timestamp":1726077419000},"page":"101732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["An overview of immune checkpoint inhibitor toxicities in bladder cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"Avenie","family":"Mavadia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunyoung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayden","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruni","family":"Ghose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joecelyn Kirani","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios","family":"Boussios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.toxrep.2024.101732_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA\u00a0Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.toxrep.2024.101732_bib2","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med. Sci. (Basel)."},{"issue":"3","key":"10.1016\/j.toxrep.2024.101732_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.toxrep.2024.101732_bib4","first-page":"43","article-title":"Non\u2014muscle-invasive bladder cancer: overview and contemporary treatment landscape of neoadjuvant chemoablative therapies","volume":"22","author":"Matulewicz","year":"2020","journal-title":"Rev. Urol."},{"issue":"6","key":"10.1016\/j.toxrep.2024.101732_bib5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.21037\/apm-22-1350","article-title":"Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence","volume":"12","author":"Uccello","year":"2023","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.toxrep.2024.101732_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231192402","article-title":"Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer","volume":"15","author":"Parent","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"2","key":"10.1016\/j.toxrep.2024.101732_bib7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clgc.2014.08.010","article-title":"Cisplatin based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy","volume":"13","author":"Necchi","year":"2015","journal-title":"Clin. Genitourin. Cancer"},{"issue":"10","key":"10.1016\/j.toxrep.2024.101732_bib8","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","article-title":"Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.toxrep.2024.101732_bib9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"issue":"6)","key":"10.1016\/j.toxrep.2024.101732_bib10","article-title":"Immune checkpoint inhibitors as a treatment option for bladder cancer: current evidence","volume":"15","author":"Okobi","year":"2023","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.toxrep.2024.101732_bib11","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.3390\/cancers14102545","article-title":"Immune checkpoint inhibitors as a neoadjuvant\/adjuvant treatment of muscle-invasive bladder cancer: a systematic review","volume":"14","author":"Barone","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.toxrep.2024.101732_bib12","doi-asserted-by":"crossref","first-page":"861","DOI":"10.21873\/anticanres.16880","article-title":"Immunotherapy combined with standard therapies in head and neck squamous cell carcinoma - a meta-analysis","volume":"44","author":"Eden","year":"2024","journal-title":"Anticancer. Res."},{"issue":"9","key":"10.1016\/j.toxrep.2024.101732_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13583","article-title":"Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary","volume":"51","author":"Rassy","year":"2021","journal-title":"Eur. J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.toxrep.2024.101732_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.toxrep.2024.101732_bib15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.21037\/atm-20-7361","article-title":"Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities","volume":"9","author":"Boussios","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"10","key":"10.1016\/j.toxrep.2024.101732_bib16","doi-asserted-by":"crossref","first-page":"8337","DOI":"10.3390\/cimb45100526","article-title":"Cardiac toxicities in oncology: elucidating the dark box in the era of precision medicine","volume":"45","author":"Samuel","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.toxrep.2024.101732_bib17","unstructured":"A. Aleem, H. Shah, Atezolizumab. StatPearls [Internet], Available from: \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK567758\/#:~:text=Many%20immune%20and%20tumor-infiltrating%20cells%20express%20programmed%20death-ligand,cytotoxic%20mediators%20leading%20to%20inhibited%20tumor%20cell%20killing\u3009 [cited 2024 Apr 4]."},{"issue":"10064","key":"10.1016\/j.toxrep.2024.101732_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"7528","key":"10.1016\/j.toxrep.2024.101732_bib19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"7528","key":"10.1016\/j.toxrep.2024.101732_bib20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"10030","key":"10.1016\/j.toxrep.2024.101732_bib21","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.toxrep.2024.101732_bib22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia\u00a0study","volume":"34","author":"McDermott","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"10031","key":"10.1016\/j.toxrep.2024.101732_bib23","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"10122","key":"10.1016\/j.toxrep.2024.101732_bib24","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"U. De Giorgi, et al., Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.toxrep.2024.101732_bib25","unstructured":"Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [Internet], Available from: \u3008https:\/\/www.nice.org.uk\/guidance\/ta525\u3009 (2018) [cited 2024 Apr 4]."},{"issue":"10236","key":"10.1016\/j.toxrep.2024.101732_bib26","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.toxrep.2024.101732_bib27","unstructured":"FDA approves avelumab for urothelial carcinoma maintenance treatment [Internet], Available from: \u3008https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment#:~:text=On%20June%2030%2C%202020%2C%20the,%2Dline%20platinum%2Dcontaining%20chemotherapy\u3009 [cited 2024 Apr 4]."},{"issue":"13","key":"10.1016\/j.toxrep.2024.101732_bib28","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.toxrep.2024.101732_bib29","unstructured":"Single Technology Appraisal Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694] Committee Papers [Internet], Available from: \u3008https:\/\/www.nice.org.uk\/guidance\/ta817\/evidence\/committee-papers-pdf-11188108765\u3009 (2021) [cited 2024 Jan 29]."},{"issue":"3","key":"10.1016\/j.toxrep.2024.101732_bib30","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"9","key":"10.1016\/j.toxrep.2024.101732_bib31","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.toxrep.2024.101732_bib32","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/OTT.S369043","article-title":"Immunotherapy for urothelial carcinoma: focus on clinical utility of nivolumab","volume":"15","author":"Chiang","year":"2022","journal-title":"Onco. Targets Ther."},{"issue":"3","key":"10.1016\/j.toxrep.2024.101732_bib33","article-title":"Advances in adoptive T-cell therapy for metastatic melanoma","volume":"71","author":"Das","year":"2023","journal-title":"Curr. Res. Transl. Med."},{"issue":"17","key":"10.1016\/j.toxrep.2024.101732_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713215","article-title":"Hallmarks of the tumour microenvironment of gliomas and its interaction with emerging immunotherapy modalities","volume":"24","author":"Linares","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.toxrep.2024.101732_bib35","unstructured":"FDA approves nivolumab for adjuvant treatment of urothelial carcinoma [Internet], Available from: \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-adjuvant-treatment-urothelial-carcinoma\u3009 [cited 2024 Jan 29]."},{"key":"10.1016\/j.toxrep.2024.101732_bib36","unstructured":"Highlights of Prescribing Information, OPVIDO (nivolumab), Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125554s097lbl.pdf\u3009 [cited 2024 Jan 29]."},{"issue":"22","key":"10.1016\/j.toxrep.2024.101732_bib37","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.toxrep.2024.101732_bib38","unstructured":"An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (CheckMate 274) [Internet], Available from: \u3008https:\/\/classic.clinicaltrials.gov\/ct2\/show\/study\/NCT02632409\u3009 [cited 2024 Jan 29]."},{"key":"10.1016\/j.toxrep.2024.101732_bib39","unstructured":"Common terminology criteria for adverse events (CTCAE) [Internet], Available from: \u3008https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40\u3009 [cited 2024 Jan 29]."},{"issue":"11","key":"10.1016\/j.toxrep.2024.101732_bib40","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.toxrep.2024.101732_bib41","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.toxrep.2024.101732_bib42","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-19-4162","article-title":"Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from checkmate 275","volume":"26","author":"Galsky","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.toxrep.2024.101732_bib43","unstructured":"Pembrolizumab (Keytruda): Advanced or Metastatic Urothelial Carcinoma [Internet], Available from: \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/pembrolizumab-keytruda-advanced-or-metastatic-urothelial-carcinoma\u3009 [cited 2024 Jan 31]."},{"issue":"11","key":"10.1016\/j.toxrep.2024.101732_bib44","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.toxrep.2024.101732_bib45","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1634\/theoncologist.2018-0084","article-title":"FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy","volume":"24","author":"Suzman","year":"2019","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.toxrep.2024.101732_bib46","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.toxrep.2024.101732_bib47","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.toxrep.2024.101732_bib48","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.toxrep.2024.101732_bib49","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): An open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.toxrep.2024.101732_bib50","unstructured":"Highlights of Prescribing information, KEYTRUDA (pembrolizumab) [Internet], Available from: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125514s066lbl.pdf\u3009 [cited 2024 Jan 31]."},{"issue":"7","key":"10.1016\/j.toxrep.2024.101732_bib51","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann. Oncol."},{"issue":"14","key":"10.1016\/j.toxrep.2024.101732_bib52","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.19.02446","article-title":"Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study","volume":"38","author":"Herbst","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.toxrep.2024.101732_bib53","first-page":"1075","article-title":"Association between duration of immunotherapy and overall survival in advanced non\u2013small cell lung cancer","volume":"9","author":"Sun","year":"2023","journal-title":"Jama\u00a0Oncol."},{"issue":"1","key":"10.1016\/j.toxrep.2024.101732_bib54","article-title":"Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes","volume":"10","author":"Li","year":"2020","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.toxrep.2024.101732_bib55","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1097\/NCC.0b013e318269040f","article-title":"Comparison between patient-reported and clinician-observed symptoms in oncology","volume":"36","author":"Xiao","year":"2013","journal-title":"Cancer Nurs."},{"key":"10.1016\/j.toxrep.2024.101732_bib56","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.toxrep.2024.101732_bib57","unstructured":"NCT04706598. Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment, \u3008https:\/\/clinicaltrials.gov\/study\/NCT04706598?cond=bladder%20cancer&term=Immunotherapy&intr=Camrelizumab&rank=1\u3009 [cited 2024 Apr 08]."},{"key":"10.1016\/j.toxrep.2024.101732_bib58","unstructured":"NCT02812420. Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery, \u3008https:\/\/clinicaltrials.gov\/study\/NCT02812420?cond=bladder%20cancer&term=Immunotherapy&intr=tremelimumab%20&rank=8\u3009 [cited 2024 Apr 08]."},{"key":"10.1016\/j.toxrep.2024.101732_bib59","unstructured":"NCT04553939. Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer, \u3008https:\/\/clinicaltrials.gov\/study\/NCT04553939?cond=bladder%20cancer&intr=Toripalimab&rank=4\u3009 [cited 2024 Apr 08]."},{"key":"10.1016\/j.toxrep.2024.101732_bib60","unstructured":"NCT04004221. Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer, \u3008https:\/\/clinicaltrials.gov\/study\/NCT04004221?cond=bladder%20cancer&intr=tislelizumab%20&rank=6\u3009 [cited 2024 Apr 08]."},{"key":"10.1016\/j.toxrep.2024.101732_bib61","unstructured":"NCT03520491. A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy. \u3008https:\/\/clinicaltrials.gov\/study\/NCT03520491?cond=bladder%20cancer&intr=ipilimumab%20&rank=1\u3009 [cited 2024 Apr 08]."},{"issue":"1","key":"10.1016\/j.toxrep.2024.101732_bib62","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"Mabs"},{"issue":"1","key":"10.1016\/j.toxrep.2024.101732_bib63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.toxrep.2024.101732_bib64","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1634\/theoncologist.2019-0129","article-title":"Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer","volume":"24","author":"Morse","year":"2019","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.toxrep.2024.101732_bib65","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/14712598.2018.1513485","article-title":"Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma","volume":"18","author":"Gao","year":"2018","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.toxrep.2024.101732_bib66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(22)00793-8","article-title":"Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2\/3 trial","volume":"24","author":"Brown","year":"2023","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.toxrep.2024.101732_bib67","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s40265-017-0782-5","article-title":"Durvalumab: first global approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.toxrep.2024.101732_bib68","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"Jama\u00a0Oncol."},{"issue":"12","key":"10.1016\/j.toxrep.2024.101732_bib69","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.toxrep.2024.101732_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11236997","article-title":"Oncolytic viruses for the treatment\u00a0of bladder cancer: advances, challenges, and prospects","volume":"11","author":"Hu","year":"2022","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.toxrep.2024.101732_bib71","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-023-01846-z","article-title":"Nadofaragene firadenovec: first approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"}],"container-title":["Toxicology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221475002400115X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221475002400115X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T12:05:45Z","timestamp":1735301145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221475002400115X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":71,"alternative-id":["S221475002400115X"],"URL":"https:\/\/doi.org\/10.1016\/j.toxrep.2024.101732","relation":{},"ISSN":["2214-7500"],"issn-type":[{"value":"2214-7500","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of immune checkpoint inhibitor toxicities in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Toxicology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxrep.2024.101732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101732"}}